ECSP15022501A - Dispersión sólida de un modulador selectivo de los receptores de progesterona - Google Patents

Dispersión sólida de un modulador selectivo de los receptores de progesterona

Info

Publication number
ECSP15022501A
ECSP15022501A ECIEPI201522501A ECPI201522501A ECSP15022501A EC SP15022501 A ECSP15022501 A EC SP15022501A EC IEPI201522501 A ECIEPI201522501 A EC IEPI201522501A EC PI201522501 A ECPI201522501 A EC PI201522501A EC SP15022501 A ECSP15022501 A EC SP15022501A
Authority
EC
Ecuador
Prior art keywords
solid dispersion
progesterone receptors
selective modulator
selective
modulator
Prior art date
Application number
ECIEPI201522501A
Other languages
English (en)
Inventor
Florian Battung
Aude Colin
Pierre-Yves Juvin
Jérôme Hecq
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47878221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15022501(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of ECSP15022501A publication Critical patent/ECSP15022501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)

Abstract

El objeto de la presente invención es una dispersión sólida que comprende un principio activo seleccionado entre el grupo que consiste en moduladores selectivos de los receptores de progesterona, metabolitos de los mismos y mezclas de los mismos, y un excipiente polimérico farmacéuticamente aceptable. La invención también se refiere a una composición farmacéutica que comprende dicha dispersión sólida y a los usos terapéuticos de la misma.
ECIEPI201522501A 2012-12-06 2015-06-05 Dispersión sólida de un modulador selectivo de los receptores de progesterona ECSP15022501A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1261721A FR2999081B1 (fr) 2012-12-06 2012-12-06 Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Publications (1)

Publication Number Publication Date
ECSP15022501A true ECSP15022501A (es) 2016-01-29

Family

ID=47878221

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201522501A ECSP15022501A (es) 2012-12-06 2015-06-05 Dispersión sólida de un modulador selectivo de los receptores de progesterona

Country Status (19)

Country Link
US (1) US20160213684A1 (es)
EP (1) EP2928499B1 (es)
JP (1) JP2016506390A (es)
CN (1) CN105120899B (es)
BR (1) BR112015013110B1 (es)
CL (1) CL2015001559A1 (es)
CR (1) CR20150299A (es)
DO (1) DOP2015000137A (es)
EA (1) EA029701B1 (es)
EC (1) ECSP15022501A (es)
ES (1) ES2666618T3 (es)
FR (1) FR2999081B1 (es)
GE (1) GEP201706740B (es)
MD (1) MD4591C1 (es)
MX (1) MX362151B (es)
NI (1) NI201500076A (es)
PE (1) PE20151783A1 (es)
UA (1) UA115796C2 (es)
WO (1) WO2014087106A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
CN111714444B (zh) * 2020-06-23 2022-12-20 南京海纳医药科技股份有限公司 一种醋酸乌利司他口服固体制剂及其制备方法
CN113406230A (zh) * 2021-06-17 2021-09-17 河南泰丰生物科技有限公司 一种醋酸乌利司他固体制剂溶出曲线的测定方法
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
JPH10505574A (ja) * 1994-07-26 1998-06-02 ラボラトワール エフィク 乾燥製剤の製造方法と、この方法で得られる医薬組成物
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
EA200970646A1 (ru) * 2006-12-28 2009-12-30 Репрос Терапьютикс Инк. Способы и составы для улучшения биодоступности антипрогестинов
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
CN102107007B (zh) * 2011-01-28 2012-11-07 广州朗圣药业有限公司 甾体类抗孕激素组合物及其制备方法
CN102600001A (zh) * 2011-01-19 2012-07-25 国家人口计生委科学技术研究所 缓释米非司酮阴道环制剂及其应用

Also Published As

Publication number Publication date
MX2015007127A (es) 2016-04-11
GEP201706740B (en) 2017-09-25
JP2016506390A (ja) 2016-03-03
EA029701B1 (ru) 2018-05-31
EA201500609A1 (ru) 2015-09-30
ES2666618T3 (es) 2018-05-07
PE20151783A1 (es) 2015-12-20
CL2015001559A1 (es) 2016-01-04
CN105120899B (zh) 2018-07-24
BR112015013110A2 (pt) 2017-07-11
UA115796C2 (uk) 2017-12-26
EP2928499B1 (fr) 2018-01-31
BR112015013110B1 (pt) 2020-07-14
FR2999081B1 (fr) 2015-02-27
MD20150060A2 (ro) 2015-10-31
US20160213684A1 (en) 2016-07-28
CR20150299A (es) 2015-08-14
FR2999081A1 (fr) 2014-06-13
EP2928499A1 (fr) 2015-10-14
CN105120899A (zh) 2015-12-02
WO2014087106A1 (fr) 2014-06-12
MD4591C1 (ro) 2019-04-30
MX362151B (es) 2018-12-24
MD4591B1 (ro) 2018-09-30
DOP2015000137A (es) 2015-08-31
NI201500076A (es) 2015-11-13

Similar Documents

Publication Publication Date Title
NI201500076A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona.
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CU20130094A7 (es) Moduladores de la vía del complemento
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
NI201500106A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno.
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
CU20160063A7 (es) Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
MX2017014621A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
UY35073A (es) Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
ECSP15022505A (es) Producto de comicronización que comprende un modulador selectivo del receptor de progesterona
CU20130159A7 (es) Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina
AR122456A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
CL2014001928A1 (es) Compuestos derivados de espiro[biciclo[3.1.0]hexano-4,1’-ciclopropano], agonistas del receptor mglu2/3; y composicion farmaceutica que los comprende.
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a